Clinical Innovations Inc

1. Otsuka Pharmaceutical Development & Commercialization, Inc. $2,433,028 32 payments
2. Teva Pharmaceuticals USA, Inc. $2,185,097 174 payments
3. Hoffmann-La Roche Limited $2,120,258 65 payments
4. ITI, Inc. $2,083,509 427 payments
5. E.R. Squibb & Sons, L.L.C. $1,546,946 9 payments
6. AbbVie, Inc. $1,410,150 62 payments
7. Moderna TX, Inc. $547,593 201 payments
8. Imbrium Therapeutics L.P. $231,370 19 payments
9. F. Hoffmann-La Roche AG $191,000 19 payments
10. Boehringer Ingelheim Pharmaceuticals, Inc. $153,334 3 payments

1. Acute Schizophrenia Study $2,259,758 66 payments
2. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $2,115,144 155 payments
3. An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $1,546,946 9 payments
4. A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder $1,465,015 2 payments
5. Iti-007-451 $1,168,461 371 payments
6. A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis $808,948 14 payments
7. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia $765,881 22 payments
8. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $381,048 14 payments
9. A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder $304,386 5 payments
10. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $277,347 6 payments

1. Patient care $68,107 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.